Shanghai Universal BiotechLtd Past Earnings Performance
Past criteria checks 0/6
Shanghai Universal BiotechLtd's earnings have been declining at an average annual rate of -6.1%, while the Healthcare industry saw earnings growing at 4.2% annually. Revenues have been growing at an average rate of 8.4% per year. Shanghai Universal BiotechLtd's return on equity is 1.3%, and it has net margins of 2.3%.
Key information
-6.1%
Earnings growth rate
-14.6%
EPS growth rate
| Healthcare Industry Growth | 7.0% |
| Revenue growth rate | 8.4% |
| Return on equity | 1.3% |
| Net Margin | 2.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Shanghai Universal BiotechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,223 | 29 | 177 | 60 |
| 31 Dec 23 | 1,226 | 40 | 172 | 59 |
| 30 Sep 23 | 1,220 | 68 | 170 | 49 |
| 30 Jun 23 | 1,267 | 100 | 162 | 47 |
| 31 Mar 23 | 1,228 | 103 | 156 | 41 |
| 31 Dec 22 | 1,195 | 106 | 145 | 32 |
| 30 Sep 22 | 1,178 | 108 | 140 | 27 |
| 30 Jun 22 | 1,104 | 98 | 129 | 21 |
| 31 Mar 22 | 1,115 | 109 | 116 | 18 |
| 01 Jan 22 | 1,110 | 109 | 112 | 16 |
| 30 Sep 21 | 1,047 | 104 | 105 | 12 |
| 30 Jun 21 | 1,017 | 100 | 104 | 11 |
| 31 Mar 21 | 915 | 84 | 100 | 10 |
| 31 Dec 20 | 849 | 76 | 94 | 9 |
| 31 Dec 19 | 787 | 58 | 94 | 9 |
| 31 Dec 18 | 604 | 40 | 73 | 6 |
| 31 Dec 17 | 432 | 26 | 56 | 3 |
| 30 Jun 17 | 376 | 21 | 49 | 0 |
| 31 Mar 17 | 359 | 21 | 44 | 0 |
| 31 Dec 16 | 342 | 21 | 40 | 0 |
| 30 Sep 16 | 315 | 17 | 41 | 0 |
| 30 Jun 16 | 287 | 14 | 39 | 0 |
| 31 Mar 16 | 260 | 11 | 36 | 0 |
| 31 Dec 15 | 232 | 9 | 33 | 0 |
| 31 Dec 14 | 162 | 7 | 22 | 0 |
| 31 Dec 13 | 109 | 1 | 20 | 0 |
Quality Earnings: 301166 has a large one-off gain of CN¥4.5M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 301166's current net profit margins (2.3%) are lower than last year (8.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301166's earnings have declined by 6.1% per year over the past 5 years.
Accelerating Growth: 301166's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301166 had negative earnings growth (-72.2%) over the past year, making it difficult to compare to the Healthcare industry average (-1%).
Return on Equity
High ROE: 301166's Return on Equity (1.3%) is considered low.